Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Shu DONG 1, 2, Ai Y. MIAO 2, 3, Wang LEI 4, Qi W. CHEN 1, 5
1 Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, PR China; 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China; 3 Department of Ultrasound, Fudan University Shanghai Cancer Center, Shanghai, PR China; 4 Department of Gastroenterology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, PR China; 5 Institute of Clinical Epidemiology, Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai, PR China
INTRODUCTION: Single nucleotide polymorphism in miRNAs can alter its expression, thus can lead to the development of cancers. Many studies have explored the association between miR-146a rs2910164 (G>C) polymorphism and hepatocellular carcinoma (HCC) risk, but the results remains inconsistent. So, we performed this pooled analyses in order to get a precise result.
EVIDENCE ACQUISITION: Odds ratios (OR) with 95% confidence intervals (CI), calculated by STATA software, was used to determine whether miR-146a rs2910164 polymorphism contributes to the risk of HCC. A comprehensive literature search was conducted on PubMed, Embase, Web of Science, and China National Knowledge Infrastructure up to May 30, 2016.
EVIDENCE SYNTHESIS: A total of 14 studies including 5921 cases and 7005 controls were included in this meta-analysis. When all the eligible studies were pooled into this meta-analysis, the miR-146a rs2910164 was associated with a decreased risk of hepatocellular carcinoma (OR = 0.90; 95% CI = 0.82-0.98, p=0.01, allele model).
CONCLUSIONS: Our meta-analysis supports that the miR-146a rs2910164 polymorphism contributs to the risk of HCC from currently available evidence.